InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,024.00
(
0.56%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
79.59
(
0.48%
)
Bitcoin
58,453.94
(
-0.46%
)
Post# of 252823
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120253
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 239380

Wednesday, 09/01/2021 8:27:10 PM

Wednesday, September 01, 2021 8:27:10 PM

Post# of 252823
Other HBV companies (e.g. ABUS) have faced a similar issue and have dealt with it in a way that I didn’t find convincing.

It’s a pretty good bet that IMCR will characterize any observed LFT abnormalities as the “good” kind (the immune system has been re-activated against the virus-laden hepatocytes) rather than the “bad” kind (the drug has liver toxicity).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up